Timothy C Nichols

List of Publications by Year
in descending order

94	4,789	117625	95266
papers	citations	34 h-index	68 g-index

94	94	94	3153
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Dexamethasone Transiently Enhances Transgene Expression in the Liver When Administered at Late-Phase Post Long-Term Adeno-Associated Virus Transduction. Human Gene Therapy, 2022, 33, 119-130.	2.7	5
2	Chimeric Mice Engrafted With Canine Hepatocytes Exhibits Similar AAV Transduction Efficiency to Hemophilia B Dog. Frontiers in Pharmacology, 2022, 13, 815317.	3.5	1
3	A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells. Nature Biotechnology, 2021, 39, 47-55.	17.5	238
4	Evolutionary insights into coagulation factor IX Padua and other high-specific-activity variants. Blood Advances, 2021, 5, 1324-1332.	5.2	12
5	Combination of Nitric Oxide Release and Surface Texture for Mitigating the Foreign Body Response. ACS Biomaterials Science and Engineering, 2021, 7, 2444-2452.	5.2	6
6	Ontogeny of the Alloimmune Anti-Canine Factor VIII Inhibitor Response in Severe Hemophilia Î‘ Dogs. Blood, 2021, 138, 3173-3173.	1.4	0
7	Development of AAV Variants with Human Hepatocyte Tropism and Neutralizing Antibody Escape Capacity. Molecular Therapy - Methods and Clinical Development, 2020, 18, 259-268.	4.1	20
8	Preclinical evaluation of a next-generation, subcutaneously administered, coagulation factor IX variant, dalcinonacog alfa. PLoS ONE, 2020, 15, e0240896.	2.5	9
9	Specific Correction of the Intron-22 Inverted Factor VIII Gene in Autologous Blood Outgrowth Endothelial Cells from Patients with Severe Hemophilia A. Blood, 2020, 136, 30-31.	1.4	1
10	Coronary Artery Disease Risk-Associated Plpp3 Gene and Its Product Lipid Phosphate Phosphatase 3 Regulate Experimental Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 2261-2272.	2.4	26
11	Superior human hepatocyte transduction with adeno-associated virus vector serotype 7. Gene Therapy, 2019, 26, 504-514.	4.5	13
12	Hemophilia A Dogs Tolerant to Human Factor VIII Provide a Unique Model to Determine Efficacy and Safety of AAV Delivery of Novel Factor VIII Variants. Blood, 2019, 134, 3628-3628.	1.4	1
13	FVIII Protein Is Not Detectable in Human PBMCs or Livers from Dogs with an Intron-22 Inversion Mutation: Implications for FVIII Immunogenicity and Tolerance. Blood, 2019, 134, 630-630.	1.4	1
14	Influence of diabetes on the foreign body response to nitric oxide-releasing implants. Biomaterials, 2018, 157, 76-85.	11.4	26
15	Complete correction of hemophilia B phenotype by FIX-Padua skeletal muscle gene therapy in an inhibitor-prone dog model. Blood Advances, 2018, 2, 505-508.	5.2	21
16	An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs. Molecular Therapy - Methods and Clinical Development, 2018, 10, 257-267.	4.1	28
17	Generation of a Unique Cohort of Hemophilia A Dogs Tolerant to Human FVIII for Evaluating the Safety and Efficacy of AAV Delivery of Wild Type and Variant Human FVIII. Blood, 2018, 132, 2453-2453.	1.4	0
18	Oral Tolerance Induction in Hemophilia B Dogs Fed with Transplastomic Lettuce. Molecular Therapy, 2017, 25, 512-522.	8.2	54

#	Article	IF	Citations
19	Performance of acoustic radiation force impulse ultrasound imaging for carotid plaque characterization with histologic validation. Journal of Vascular Surgery, 2017, 66, 1749-1757.e3.	1.1	25
20	Evaluation of engineered AAV capsids for hepatic factor IX gene transfer in murine and canine models. Journal of Translational Medicine, 2017, 15, 94.	4.4	16
21	Global measurement of coagulation in plasma from normal and haemophilia dogs using a novel modified thrombin generation test â€“ Demonstrated in vitro and ex vivo. PLoS ONE, 2017, 12, e0175030.	2.5	3
22	Sustained correction of FVII deficiency in dogs using AAV-mediated expression of zymogen FVII. Blood, 2016, 127, 565-571.	1.4	19
23	Soy Phosphatidylinositolâ€“Containing Lipid Nanoparticle Prolongs the Plasma Survival and Hemostatic Efficacy of B-domainâ€“Deleted Recombinant Canine Factor VIII in Hemophilia A Dogs. Journal of Pharmaceutical Sciences, 2016, 105, 2459-2464.	3.3	4
24	ExÂVivo Porcine Arterial and Chorioallantoic Membrane Acoustic Angiography Using Dual-Frequency Intravascular Ultrasound Probes. Ultrasound in Medicine and Biology, 2016, 42, 2294-2307.	1.5	20
25	Experimental Validation of ARFI Surveillance of Subcutaneous Hemorrhage (ASSH) Using Calibrated Infusions in a Tissue-Mimicking Model and Dogs. Ultrasonic Imaging, 2016, 38, 346-358.	2.6	6
26	Severe Hemophilia A in a Male Old English Sheep Dog with a Câ†'T Transition that Created a Premature Stop Codon in Factor VIII. Comparative Medicine, 2016, 66, 405-411.	1.0	3
27	Oxidized LDL and Fructosamine Associated with Severity of Coronary Artery Atherosclerosis in Insulin Resistant Pigs Fed a High Fat/High NaCl Diet. PLoS ONE, 2015, 10, e0132302.	2.5	10
28	Non-invasive inÂVivo Characterization of Human Carotid Plaques with Acoustic Radiation Force Impulse Ultrasound: Comparison with Histology after Endarterectomy. Ultrasound in Medicine and Biology, 2015, 41, 685-697.	1.5	66
29	Translational Data from Adeno-Associated Virus-Mediated Gene Therapy of Hemophilia B in Dogs. Human Gene Therapy Clinical Development, 2015, 26, 5-14.	3.1	29
30	Targeted Disruption of LDLR Causes Hypercholesterolemia and Atherosclerosis in Yucatan Miniature Pigs. PLoS ONE, 2014, 9, e93457.	2.5	90
31	In vivo ARFI surveillance of subcutaneous hemorrhage (ASSH) for monitoring rcFVIII dose response in hemophilia A dogs. , 2014, , .		1
32	In vivo characterization of atherosclerotic plaque of human carotid arteries with histopathological correlation using ARFI ultrasound. , 2014, , .		1
33	Portal Vein Delivery of Viral Vectors for Gene Therapy for Hemophilia. Methods in Molecular Biology, 2014, 1114, 413-426.	0.9	10
34	Lessons Learned from Animal Models of Inherited Bleeding Disorders. Hematology Education, 2014, 8, 39-46.	0.0	1
35	Animal Models of Hemophilia and Related Bleeding Disorders. Seminars in Hematology, 2013, 50, 175-184.	3.4	34
36	Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A. Nature Communications, 2013, 4, 2773.	12.8	102

#	Article	IF	Citations
37	The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy. Blood, 2012, 120, 4521-4523.	1.4	100
38	Animal Models of Hemophilia. Progress in Molecular Biology and Translational Science, 2012, 105, 151-209.	1.7	62
39	Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs. Blood, 2012, 119, 3024-3030.	1.4	139
40	In vivo detection of hemorrhage rate in dog models of hemophilia and VWD and at human femoral arteriotomy by ARFI ultrasound. , 2011, , .		0
41	Efficacy and Safety of Long-term Prophylaxis in Severe Hemophilia A Dogs Following Liver Gene Therapy Using AAV Vectors. Molecular Therapy, 2011, 19, 442-449.	8.2	116
42	Phase II Biologic Effects Trial of Recombinant Interleukin-11 (rhIL-11, Neumega) in Moderate or Mild Hemophilia A or Von Willebrand Disease Unable to Use DDAVP,. Blood, 2011, 118, 3308-3308.	1.4	0
43	Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B. Blood, 2010, 115, 4678-4688.	1.4	104
44	Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy. Blood, 2010, 116, 5842-5848.	1.4	144
45	Porcine and Canine von Willebrand Factor and von Willebrand Disease: Hemostasis, Thrombosis, and Atherosclerosis Studies. Thrombosis, 2010, 2010, 1-11.	1.4	22
46	Safety of AAV Factor IX Peripheral Transvenular Gene Delivery to Muscle in Hemophilia B Dogs. Molecular Therapy, 2010, 18, 1318-1329.	8.2	66
47	Magnetic and Contrast Properties of Labeled Platelets for Magnetomotive Optical Coherence Tomography. Biophysical Journal, 2010, 99, 2374-2383.	0.5	38
48	ARFI ultrasound for in vivo monitoring of soft-tissue bleeding and hemostasis in a dog model of hemophilia. , 2010, , .		0
49	De Novo Synthesis & Storage of Human Factor VIII In Platelets Reduces Bleeding In Canine Hemophilia A. Blood, 2010, 116, 2198-2198.	1.4	1
50	Protein Replacement Therapy and Gene Transfer in Canine Models of Hemophilia A, Hemophilia B, von Willebrand Disease, and Factor VII Deficiency. ILAR Journal, 2009, 50, 144-167.	1.8	71
51	Blood outgrowth endothelial cell migration and trapping in vivo: a window into gene therapy. Translational Research, 2009, 153, 179-189.	5.0	32
52	Reflected shear wave imaging of atherosclerosis. , 2009, , .		1
53	Successful treatment of canine hemophilia by continuous expression of canine FVIIa. Blood, 2009, 113, 3682-3689.	1.4	79
54	Recombinant canine B-domainâ€“deleted FVIII exhibits high specific activity and is safe in the canine hemophilia A model. Blood, 2009, 114, 4562-4565.	1.4	55

#	Article	IF	Citations
55	ISOLATION AND CHARACTERIZATION OF BIORESPONSIVE RENAL CELLS FROM HUMAN AND LARGE MAMMAL WITH CHRONIC RENAL FAILURE. FASEB Journal, 2009, 23, LB143.	0.5	1
56	The interaction of factor VIIa with rehydrated, lyophilized platelets. Platelets, 2008, 19, 182-191.	2.3	8
57	Comparison of multiple beam sequences in arterial ARFI imaging, ex vivo. , 2008, , .		1
58	Successful and Safe Treatment of Canine Hemophilia by Continuous Expression of Canine FVIIa: a Model for FVIII/FIX Gene-Based Bypassing Agents. Blood, 2008, 112, lba-4-lba-4.	1.4	0
59	Immune response after neonatal transfer of a human factor IX-expressing retroviral vector in dogs, cats, and mice. Thrombosis Research, 2007, 120, 269-280.	1.7	35
60	Long-Term Efficacy of Adeno-Associated Virus Serotypes 8 and 9 in Hemophilia A Dogs and Mice. Human Gene Therapy, 2006, 17, 427-439.	2.7	95
61	Long-Term Efficacy of Adeno-associated Virus Serotypes 8 and 9 in Hemophilia A Dogs and Mice. Human Gene Therapy, 2006, .	2.7	0
62	Long Term Dose-Dependent Correction of Hemophilia A Dogs Using AAV-8 and AAV-9-Mediated FVIII Gene Transfer.. Blood, 2006, 108, 999-999.	1.4	0
63	Recombinant Human IL-11 (rhIL-11, NeumegaÂ®) Increases VWF Activity in Type 1 Von Willebrand Disease.. Blood, 2006, 108, 1003-1003.	1.4	0
64	Re-establishment of VWF-dependent Weibel-Palade bodies in VWD endothelial cells. Blood, 2005, 105, 145-152.	1.4	59
65	Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model. Blood, 2005, 105, 3458-3464.	1.4	144
66	Absence of a desmopressin response after therapeutic expression of factor VIII in hemophilia A dogs with liver-directed neonatal gene therapy. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 6080-6085.	7.1	68
67	Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy. Blood, 2005, 105, 3079-3086.	1.4	162
68	Sustained Phenotypic Correction of Canine Hemophilia B After Systemic Administration of Helper-Dependent Adenoviral Vector. Human Gene Therapy, 2005, 16, 811-820.	2.7	74
69	Gene Transfer to Macrophages with Nanoparticle-Loaded Platelets.. Blood, 2005, 106, 3043-3043.	1.4	0
70	Use of Engineered Autologous BOEC for Gene Therapy of Canine Hemophilia A.. Blood, 2005, 106, 1281-1281.	1.4	0
71	Interaction of Recombinant Factor VIIa with Rehydrated, Lyophilized Platelets.. Blood, 2005, 106, 3994-3994.	1.4	0
72	Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1. Blood, 2004, 103, 85-92.	1.4	147

#	Article	IF	Citations
73	A Novel Method of Regional Intravenous Delivery of AAV Vector to Skeletal Muscle Results in Correction of Canine Hemophilia B Phenotype.. Blood, 2004, 104, 3179-3179.	1.4	5
74	DDAVP-Induced Increase of Factor VIII Activity in Blood Is Likely Due To Release of Factor VIII That Is Synthesized by Endothelial Cells.. Blood, 2004, 104, 692-692.	1.4	1
75	NF-kappaB and reperfusion injury. Drug News and Perspectives, 2004, 17, 99.	1.5	98
76	Neonatal or hepatocyte growth factorâ€“potentiated adult gene therapy with a retroviral vector results in therapeutic levels of canine factor IX for hemophilia B. Blood, 2003, 101, 3924-3932.	1.4	105
77	A gene-deleted adenoviral vector results in phenotypic correction of canine hemophilia B without liver toxicity or thrombocytopenia. Blood, 2003, 102, 2403-2411.	1.4	76
78	Reduced bleeding events with subcutaneous administration of recombinant human factor IX in immune-tolerant hemophilia B dogs. Blood, 2003, 102, 4393-4398.	1.4	40
79	Influence of Vector Dose on Factor IX-Specific T and B Cell Responses in Muscle-Directed Gene Therapy. Human Gene Therapy, 2002, 13, 1281-1291.	2.7	149
80	The Chapel Hill hemophilia A dog colony exhibits a factor VIII gene inversion. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 12991-12996.	7.1	100
81	Thrombus Formation with Rehydrated, Lyophilized Platelets. Hematology, 2002, 7, 359-369.	1.5	27
82	Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood, 2002, 99, 2670-2676.	1.4	333
83	SPLENIC CLEARANCE MECHANISMS OF REHYDRATED, LYOPHILIZED PLATELETS. Artificial Cells, Blood Substitutes, and Biotechnology, 2001, 29, 439-451.	0.9	28
84	Role of Nuclear Factor-Kappa B (NF-Î¹B) in Inflammation, Periodontitis, and Atherogenesis. , 2001, 6, 20-29.		81
85	Lack of Germline Transmission of Vector Sequences Following Systemic Administration of Recombinant AAV-2 Vector in Males. Molecular Therapy, 2001, 4, 586-592.	8.2	152
86	Intratracheal administration of recombinant human factor IX (BeneFix) achieves therapeutic levels in hemophilia B dogs. Thrombosis and Haemostasis, 2001, 85, 445-9.	3.4	5
87	Intracellular function in rehydrated lyophilized platelets. British Journal of Haematology, 2000, 111, 167-174.	2.5	4
88	Sustained Expression of Therapeutic Level of Factor IX in Hemophilia B Dogs by AAV-Mediated Gene Therapy in Liver. Molecular Therapy, 2000, 1, 154-158.	8.2	171
89	Intracellular function in rehydrated lyophilized platelets. British Journal of Haematology, 2000, 111, 167-174.	2.5	25
90	Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nature Medicine, 1999, 5, 56-63.	30.7	549

#	Article	IF	Citations
91	Failure to Achieve Gene Conversion with Chimeric Circular Oligonucleotides: Potentially Misleading PCR Artifacts Observed. Oligonucleotides, 1998, 8, 531-536.	4.3	38
92	von Willebrand Factor Does Not Influence Atherogenesis in Arteries Subjected to Altered Shear Stress. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 323-330.	2.4	13
93	Thrombotic Thrombocytopenia Induced in Dogs and Pigs. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 793-800.	2.4	30
94	Von Willebrand Factor and Animal Models: Contributions to Gene Therapy, Thrombotic Thrombocytopenic Purpura, and Coronary Artery Thrombosis. Mayo Clinic Proceedings, 1991, 66, 733-742.	3.0	33